# Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib

> **NCT05848219** · — · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 543 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05848219
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-16
- **Primary completion:** 2022-04-27
- **Final completion:** 2022-04-27
- **Target enrollment:** 543 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2023-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05848219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05848219, "Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05848219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*